[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Biogen's Q2 2026 Earnings: What to Expect

With a market cap of $29.6 billion, Biogen Inc. (BIIB) is a leading biotechnology company dedicated to pioneering innovative science to develop transformative medicines that improve patients' lives. By leveraging a deep understanding of human biology and advanced therapeutic approaches, the company strives to deliver first-in-class treatments while creating long-term value for shareholders and communities.

The Cambridge, Massachusetts-based company is set to unveil its fiscal Q2 2026 results before the market opens on Wednesday, Jul. 29. Ahead of this event, analysts expect BIIB to report an adjusted EPS of $3.24, down 40.8% from $5.47 in the year-ago quarter. However, it has...

Fundamentals

See More
  • Market Capitalization, $K 29,580,548
  • Shares Outstanding, K 147,637
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,420 M
  • EBITDA $ 3,493 M
  • 60-Month Beta 0.16
  • Price/Sales 3.07
  • Price/Cash Flow 9.09
  • Price/Book 1.63

Options Overview Details

View History
  • Implied Volatility 43.41% (-0.23%)
  • Historical Volatility 35.64%
  • IV Percentile 89%
  • IV Rank 68.07%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 7) 10.58 (5.32%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 1,097
  • Volume Avg (30-Day) 1,458
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 54,705
  • Open Int (30-Day) 52,934
  • Expected Range 188.33 to 209.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.21
  • Number of Estimates 19
  • High Estimate $3.99
  • Low Estimate $2.33
  • Prior Year $5.47
  • Growth Rate Est. (year over year) -41.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
193.20 +2.96%
on 06/18/26
219.72 -9.47%
on 06/29/26
-0.19 (-0.10%)
since 06/09/26
3-Month
171.22 +16.17%
on 04/13/26
219.72 -9.47%
on 06/29/26
+21.80 (+12.31%)
since 04/09/26
52-Week
121.05 +64.32%
on 07/21/25
219.72 -9.47%
on 06/29/26
+65.89 (+49.53%)
since 07/09/25

Most Recent Stories

More News
Biogen's Q2 2026 Earnings: What to Expect

Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.

XLV : 162.17 (-0.08%)
$SPX : 7,543.64 (+0.81%)
BIIB : 198.91 (-0.72%)
1 S&P 500 Stock with Promising Prospects and 2 We Question

1 S&P 500 Stock with Promising Prospects and 2 We Question

FOXA : 53.74 (+0.66%)
GEV : 1,075.26 (+0.40%)
BIIB : 198.91 (-0.72%)
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027...

STOK : 32.83 (+0.55%)
BIIB : 198.91 (-0.72%)
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline...

BIIB : 198.91 (-0.72%)
Why Biogen (BIIB) Stock Is Up Today

Why Biogen (BIIB) Stock Is Up Today

BIIB : 198.91 (-0.72%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 198.91 (-0.72%)
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

QNTM : 3.41 (+4.28%)
QNTM.CN : 4.8100 (+8.09%)
CLNN : 6.25 (+2.80%)
RHHBY : 52.0200 (+0.50%)
SNY : 43.90 (+2.62%)
BIIB : 198.91 (-0.72%)
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)

Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)

BIIB : 198.91 (-0.72%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 198.91 (-0.72%)
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule...

BIIB : 198.91 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 206.29
2nd Resistance Point 203.65
1st Resistance Point 201.28
Last Price 198.91
1st Support Level 196.27
2nd Support Level 193.63
3rd Support Level 191.26

See More

52-Week High 219.72
Last Price 198.91
Fibonacci 61.8% 182.03
Fibonacci 50% 170.39
Fibonacci 38.2% 158.74
52-Week Low 121.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.